The irony is that the committee considered the public summary document issue at its intracycle meeting in May this year. It was not included on any agenda and the first anyone heard of it was through informal mentions and when the outcomes were officially published in late June - so, achieving greater transparency with no transparency.
Latest Video
New Stories
-
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News -
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Novo Nordisk appoints Michael Azrak as new Oceania General Manager
December 1, 2025 - - Latest News -
New PBS listing brings immunotherapy option to Australians with rare head and neck cancer
December 1, 2025 - - Latest News -
DBG Health appoints Matt Zeller to lead Arrotex Pharmaceuticals into its next phase of growth
December 1, 2025 - - Latest News -
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 - - Australian Biotech -
Melbourne showcases its health and biomedical strength as leaders gather for National Precincts Summit
December 1, 2025 - - Australian Biotech
